China’s rapid growth in innovative medicines is reshaping the global pharmaceutical industry, moving away from generic drugs to first-class therapies. The country leads in global clinical trials and drug licensing deals, with Western companies seeking collaborations. A looming patent cliff fuels the urgency for cost-effective, high-quality therapies.

China’s pharma sector sees a surge in high-value deals with the West, with Novartis, AstraZeneca, and Zenas Biopharma striking multi-billion dollar agreements. Experts predict continued growth in dealmaking between China and the West, driven by the cost-effective early clinical programs in China.

The value of Chinese drug asset deals rises, focusing on oncology therapies. Antibody-drug conjugates (ADCs) and next-generation biologics like bispecifics and cell and gene therapies (CGTs) drive investor interest. China emerges as a key hub for CGTs, attracting attention with rapid trials and innovative therapies.

Oncology remains a key focus for Chinese biotech and pharma, with ADCs developed in China gaining popularity among Western dealmakers. Immunology and cardiometabolic health also see increased deal activity as companies aim to tap into competitive markets.

The BIOSECURE Act’s reintroduction in the US could impact interactions between the West and China, but industry leaders remain undeterred. Focus on innovation and first-class drugs reduces concerns over geopolitical events, maintaining positive partnerships between US and Chinese biotech companies.

Some Chinese companies opt for a global self-commercialisation strategy over traditional licensing deals, exemplified by BeOne Medicines’ success. While this trend gains traction, most companies still rely on MNC partnerships due to trial experience and R&D capabilities.

Long-term growth in China’s pharma sector may lead to US pharma lobbying to restrict their expansion. As Chinese companies aim for self-commercialisation, continued capital access and experience building through partnerships will be crucial for their success in the global market.

Read more at Yahoo Finance: High-value oncology deals drive China’s drug licensing boom